Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20365049 | 1.00 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3278728 | 1.00 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL7814587 | 0.97 | HTR6 (0.54) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL29082713 | 0.97 | HTR6 (0.54) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3810047 | 0.97 | — | — | |
| Bromide SCHEMBL28560892 | 0.94 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL22607680 | 0.94 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL3258445 | 0.94 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3056808 | 0.91 | — | — | |
| SCHEMBL22737698 | 0.90 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1MBTD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661047-A | Benzothiadiazoles amines | 拜耳制药股份公司 | 2017-05-10 | — | — | CN | claimed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024140319-A1 | PYRIMIDINE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255760-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11878977-B2 | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010062848-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIKANA THERAPEUTICS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | ALBIREO AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| US-5442044-A | Hypotensive agents | PFIZER INC. (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0661292-A1 | Orally active renin inhibitors | PFIZER INC. (US) | 1995-07-05 | — | — | EP | disclosed |
| EP-0438233-A2 | Orally active renin inhibitors | PFIZER INC. (US) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878977-B2 | JAK inhibitors containing a 4-membered heterocyclic amide | JAK1, JAK2, JAK3 | HTR6 3601/4885FYN 260/4885L3MBTL3 4226/4885 |
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | GIPR, HRH2, BDKRB2 | HTR6 220/4885FYN 3143/4885L3MBTL3 4885/4885 |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | HTR6 175/4885FYN 3675/4885L3MBTL3 1120/4885 |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HTR6 361/4885FYN 4296/4885L3MBTL3 4615/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | HTR6 2117/4885FYN 1350/4885L3MBTL3 1287/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | HTR6 3928/4885FYN 3159/4885L3MBTL3 2475/4885 |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | HTR6 2094/4885FYN 3699/4885L3MBTL3 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.